High-flow nasal cannula versus conventional oxygen therapy in acute COPD exacerbation with mild hypercapnia: a multicenter randomized controlled trial

Jingen Xia1,2,3,4†, Sichao Gu1,2,3,4†, Wei Lei6†, Jihua Zhang7†, Hui Wei8, Chao Liu6, Han Zhang9, Rongli Lu10, Liqiong Zhang7, Mingyan Jiang11, Chao Hu11, Zhenshun Cheng12,13, Chaojie Wei12,13, Yusheng Chen14, Fengfeng Lu14, Min Chen15, Hong Bi15, Hui Liu16, Cunzi Yan16, Hong Teng17,18, Yang Yang17,18, Chen Liang19, Yanlei Ge20, Pengguo Hou21, Jialin Liu22, Weiwei Gao23, Yi Zhang12,3,4, Yingying Feng12,3,4, Cheng Tao1,2,3,4, Xu Huang1,2,3,4, Pinhua Pan10*, Hong Luo9*, Chunmei Yun8* and Qingyuan Zhan1,2,3,4*

Abstract

Background: High-flow nasal cannula (HFNC) can improve ventilatory function in patients with acute COPD exacerbation. However, its effect on clinical outcomes remains uncertain.

Methods: This randomized controlled trial was conducted from July 2017 to December 2020 in 16 tertiary hospitals in China. Patients with acute COPD exacerbation with mild hypercapnia (pH ≥ 7.35 and arterial partial pressure of carbon dioxide > 45 mmHg) were randomly assigned to either HFNC or conventional oxygen therapy. The primary outcome was the proportion of patients who met the criteria for intubation during hospitalization. Secondary outcomes included treatment failure (intolerance and need for non-invasive or invasive ventilation), length of hospital stay, hospital cost, mortality, and readmission at day 90.

Results: Among 337 randomized patients (median age, 70.0 years; 280 men [83.1%]; median pH 7.399; arterial partial pressure of carbon dioxide 51 mmHg), 330 completed the trial. 4/158 patients on HFNC and 1/172 patient on conventional oxygen therapy met the criteria for intubation (P = 0.198). Patients progressed to NPPV in both groups were comparable (15 [9.5%] in the HFNC group vs. 22 [12.8%] in the conventional oxygen therapy group; P = 0.343).

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Compared with conventional oxygen therapy, HFNC yielded a significantly longer median length of hospital stay (9.0 [interquartile range, 7.0–13.0] vs. 8.0 [interquartile range, 7.0–11.0] days) and a higher median hospital cost (approximately $2298 [interquartile range, $1613–$3782] vs. $2005 [interquartile range, $1439–$2968]). There were no significant differences in other secondary outcomes between groups.

**Conclusions:** In this multi-center randomized controlled study, HFNC compared to conventional oxygen therapy did not reduce need for intubation among acute COPD exacerbation patients with mild hypercapnia. The future studies should focus on patients with acute COPD exacerbation with respiratory acidosis (pH < 7.35). However, because the primary outcome rate was well below expected, the study was underpowered to show a meaningful difference between the two treatment groups.

**Trial registration:** NCT03003559. Registered on December 28, 2016.

**Keywords:** High-flow nasal cannula, Respiratory support, Respiratory insufficiency, Pulmonary disease, Chronic obstructive, Hypercapnia

---

**Background**

Non-invasive positive pressure ventilation (NPPV) can significantly reduce the need for intubation and the in-hospital mortality rate among patients with acute chronic obstructive pulmonary disease (COPD) exacerbation with respiratory acidosis [1–3]. However, it is currently not recommended for use in mild hypercapnic acute COPD exacerbations without acute respiratory acidosis (pH ≤ 7.35) [4]. Therefore, conventional oxygen therapy (COT) is the most commonly used standard treatment for these patients [2]. However, COT is often associated with a variable fraction of inspired oxygen (FiO2), dryness of the nose and mouth, nasal mucosal bleeding, and intolerance. Moreover, several previous studies have reported that 7–15% of COPD patients who experience acute exacerbation with COT require upgrading to invasive mechanical ventilation [5–7], which is an indicator of an important increased mortality risk [1–4].

High-flow nasal cannula (HFNC) is a novel modality of respiratory support technology that has emerged for use in adult patients with acute respiratory failure over the past decade [8]. It has been proved to have several remarkable physiological advantages [8–12]. Several recent meta-analyses [11–13] found that HFNC can reduce the risk of endotracheal intubation in patients with acute hypoxic respiratory failure when compared with COT. It is noteworthy that most randomized controlled trials exploring the use of HFNC in acute respiratory failure have excluded hypercapnic patients [14–16].

Recently, physiological studies of small samples of acute exacerbations and stable COPD patients found that short-term (within 2 h) application of HFNC could effectively decrease the arterial partial pressure of carbon dioxide (PaCO2) by 4%-12% [17–20], reduce the physiological dead space [17–21], attenuate the work of breathing [22–24], and improve airway clearance [25]. Two randomized controlled trials [26, 27] reported that compared with long-term oxygen therapy, long-term (6 weeks to 1 year) HFNC therapy can further improve the quality of life and reduce the risk of readmission due to acute exacerbations among patients with stable COPD. However, the effect of HFNC on clinical outcomes in patients with acute COPD exacerbation with mild hypercapnia remains uncertain.

Therefore, in this randomized controlled trial, we hypothesized that compared to COT, HFNC would reduce the need for intubation for acute COPD exacerbation patients with mild hypercapnia (pH ≥ 7.35, PaCO2 > 45 mmHg).

**Methods**

**Study design**

This randomized clinical trial was conducted in the general respiratory wards of 16 tertiary hospitals in China from July 2017 to December 2020. The ethics committee of each hospital approved the study protocol. An investigator at each hospital was responsible for daily patient screening, selection, randomization, and electronic data recording, as per the study protocol. The investigators did not participate in the daily medical care of the enrolled patients. All patients or their relatives provided written informed consent.

**Study participants**

All patients admitted to the hospital with a main diagnosis of acute COPD exacerbation according to GOLD criteria were enrolled if they had mild hypercapnia (pH ≥ 7.35 and PaCO2 > 45 mmHg) at admission.

The main exclusion criteria were age > 85 years, Glasgow Coma Scale score < 12, home NPPV, obstructive sleep apnoea syndrome, excessive airway secretions that are difficult to drain, hemodynamic instability (systolic blood pressure < 90 mmHg, mean blood pressure < 65 mmHg, or blood pressure lower than the baseline value of 40 mmHg, and a lactate level > 2 mmol/L among patients receiving vasoactive drugs), severe...
arrhythmia or acute coronary syndrome, respiratory and cardiac arrest, palliative care, refusal to be included in this study, or participation in other studies.

At inclusion, demographic variables (age, sex, acute physiology and chronic health evaluation [APACHE II score, and comorbidities) were recorded. In the 72 h after randomization, the following variables were recorded: arterial blood gas, oxygen saturation (SpO₂), Borg dyspnoea scale score, subjective airway (oral, nasal, and throat) dryness score (0–10 scale, on which 0 is normal and 10 is severest form of dryness), laboratory biochemical indexes, and vital signs. Patients were followed up for 90 days after randomization.

Randomization
The randomization scheme was computer generated using a centralized Web-based management system in permuted blocks of four or six participants, with stratification according to the center. The patient ID number was required for randomization, and each ID number was randomized only once. The patients were randomly divided into a HFNC group (intervention group) or a COT group (control group) in a 1:1 ratio.

Interventions
All patients in the HFNC group received HFNC therapy using Airvo-2TM equipment (Fisher & Paykel Healthcare, Auckland, New Zealand). According to the published literature [20–22], the initial HFNC flow rate was set to 25 L/min to improve ventilatory function and gradually increased (5–10 L/min each time) to patient’s maximum tolerance. The FiO₂ was adjusted to maintain a SpO₂ between 90 and 95%. The inhaled gas temperature (31–37 °C) was set at the patient’s maximum tolerance level. HFNC therapy was recommended for use as long as possible every day. HFNC treatment was withdrawn once the flow rate and FiO₂ were lower than 20 L/min and 0.3, respectively.

Patients in the COT group received continuously low flow oxygen therapy via a nasal cannula. Moreover, the oxygen flow rate in the nasal cannula (1–5 L/min) was titrated to maintain an SpO₂ of 90–95%.

Outcomes
The primary outcome was the proportion of patients who met the criteria for intubation (need for intubation) during hospitalization. The need for intubation was a more objective and uniform variable, avoiding inconsistencies associated with intubation affected by multiple factors, including ICU bed and equipment availability, physician’s experience, etc. The criteria for intubation and invasive mechanical ventilation included intolerance of NPPV, severe acute respiratory failure in which NPPV was difficult to correct, pH<7.25 accompanied by a progressive increase in PaCO₂, respiratory or cardiac arrest, loss of consciousness and delirium, massive aspiration, inability to clear airway secretions, severe hemodynamic instability, severe arrhythmia, and life-threatening hypoxemia.

The secondary outcomes were the rate of treatment failure (intolerance, need for intubation, or NPPV), daily duration of HFNC and COT treatment during the first 7 days (the day of randomization was called day one), proportion of patients upgraded to NPPV, actual intubation rate, length of hospital stay, hospital cost (the sum of all expenses incurred during hospitalization, including bed cost, instrumental examination cost, lab investigation cost, treatment cost, drug cost, nursing care cost, and medical consumables, etc., but excluding the cost of HFNC circuits), mortality rate in the hospital and at day 90, and the readmission rate after discharge due to acute exacerbations at day 90. The criteria for NPPV treatment included worsening respiratory acidosis (pH<7.35), severe dyspnoea, respiratory muscle fatigue, or increased work of breathing (e.g., accessory respiratory muscle score ≥3) [28], and severe hypoxemia (PaO₂ < 50 mmHg). The respiratory support modality (nasal cannula, NPPV, or invasive mechanical ventilation) after treatment failure in both groups was determined by consultation with the attending physician and the patient.

Exploratory outcomes included blood gas, Borg dyspnoea scale score and airway dryness score at 2, 24, 48, and 72 h after randomization, and adverse events.

Statistical analysis
According to a previous publication [6], the proportion of patients meeting the criteria for intubation was 11.3% among patients with mild acute COPD exacerbation (pH>7.35) using nasal cannula. Due to the absence of previous clinical trials that investigated the use of HFNC for milder acute COPD exacerbations, assuming the proportion of patients meeting the criteria for intubation of 3% after application of HFNC, a total sample size of 328 patients was required to achieve a power of 80% to detect the difference at a two-sided alpha level of 0.05, after accounting for a loss to follow-up rate of 10%.

All analyses were conducted according to the intention-to-treat principle. Data for continuous variables with normal and skewed distributions were reported as means or medians and standard deviations or interquartile ranges (IQRs), respectively. Categorical variables were reported as frequencies and percentages. For group comparisons of efficacy and safety endpoints, the student t-test was used for variables with normal distributions, the Mann–Whitney U test was applied to skewed variables, and Pearson’s Chi-squared test or Fisher’s exact test was performed for categorical variables. We
used time-to-event methods, including Kaplan–Meier curves and log-rank tests, to compare the overall survival within 90 days after intervention and the time to readmission within 90 days after randomization between the intervention and control groups. We applied a post hoc random-effect regression model to adjust for center for the primary outcome. The cumulative incidence function and Gray’s test were used to consider deaths as competing events to evaluate the difference of time to readmission for acute exacerbation between two groups.

All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Statistical items with a two-sided \( P \)-value < 0.05 were considered statistically significant.

**Results**

**Study participants**

During the study period, 1276 patients with acute COPD exacerbation with mild hypercapnia were identified, 337 (median age, 70.0 years; 280 men [83.1%]) of whom were randomized. Seven patients were secondarily excluded because they had missing data for the primary outcome (\( n = 4 \)) or withdrew informed consent (\( n = 3 \)). The remaining 330 patients were included in the analysis: 158 in the HFNC group and 172 in the COT group (Fig. 1 and Table 1).

**HFNC treatment**

The initial median settings in the HFNC group were as follows: flow rate, 30.0 L/min (IQR, 25.0–40.0); \( \text{FiO}_2 \), 0.32 (IQR, 0.3–0.4); and gas temperature, 31.0 °C (IQR, 31.0–34.0) (Additional file 1: Table S1). Within 7 days of randomization, the total median duration of HFNC treatment was 82.0 h (IQR, 44.0–137.0), which was shorter than that of nasal cannula in the COT group (111.0 h [IQR, 66.0–148.5]) (\( P = 0.005 \)) (Additional file 1: Table S1). Moreover, the daily treatment duration of HFNC was also shorter than that of nasal cannula in the COT group within 7 days after randomization (Additional file 2: Table S2).

![Fig. 1 Flow of participants through study](image-url)
Table 1  Baseline patient characteristics

| Characteristic                                      | High-flow nasal cannula group (n = 158) | Conventional oxygen therapy group (n = 172) |
|----------------------------------------------------|----------------------------------------|--------------------------------------------|
| **Characteristics of the patients at admission**    |                                        |                                            |
| Age, median (IQR), y                               | 70.0(65.0–75.0)                        | 69.0(63.5–74.5)                            |
| Men, No. (%)                                       | 140(88.6%)                             | 137(79.7%)                                |
| Body mass index*, median (IQR), kg/m²               | 21.0(18.7–23.3)                        | 21.0(18.7–23.3)                           |
| APACHE II score, median (IQR)                       | 10.0(7.0–13.0)                         | 10.0(7.0–13.5)                            |
| Symptoms at admission, No. (%)                     | 149(94.3%)                             | 170(98.8%)                                |
| Dyspnoea                                           | 143(90.5%)                             | 157(91.3%)                                |
| Cough                                              | 118(74.4)                              | 138(80.2%)                                |
| Sputum production                                  | 101(63.9%)                             | 91(52.9%)                                 |
| Fever                                              | 24(15.2%)                              | 24(14%)                                   |
| Comorbidities, No. (%)                             |                                        |                                            |
| Hypertension                                       | 54(34.2%)                              | 65(37.8%)                                 |
| Diabetes mellitus                                  | 16(10.1%)                              | 13(7.6%)                                  |
| Asthma                                             | 11(7.0%)                               | 8(4.7%)                                   |
| Chronic heart failure                              | 7(4.4%)                                | 12(7.0%)                                  |
| Bronchiectasis                                     | 7(4.4%)                                | 10(5.8%)                                  |
| Current smoker, No. (%)                            | 34(21.5%)                              | 35(20.3%)                                 |
| FEV1% predicted, No                                | 59                                     | 67                                         |
| Median (IQR)                                       | 32.5(24.8–42.1)                        | 32.0(24.6–43.1)                           |
| FEV1/FVC% predicted, No                            | 60                                     | 67                                         |
| Median (IQR)                                       | 41.6(33.0–51.3)                        | 42.6(34.6–51.6)                           |
| Prior use of long-term oxygen therapy, No. (%)     | 37(23.4%)                              | 40(23.3%)                                 |
| **Physiological characteristics at randomization**  |                                        |                                            |
| Body temperature, median (IQR), °C                 | 36.5(36.4–36.8)                        | 36.6(36.4–36.8)                           |
| Respiratory rate, median (IQR), breaths/min        | 21.0(20.0–23.0)                        | 21.0(20.0–23.0)                           |
| Heart rate, median (IQR), beats/min                | 85.0(78.0–98.0)                        | 88.5(78.5–100.0)                          |
| Mean blood pressure, median (IQR), mmHg            | 95.0(87.3–102.7)                       | 96.0(88.7–102.8)                          |
| SpO₂ median (IQR), %                               | 93.0(89.0–96.0)                        | 92.0(88.0–96.0)                           |
| Nasal cannula, No. (%)                             | 89(56.3%)                              | 98(57.0%)                                 |
| O₂ flow, median (IQR), L/min                       | 2.0(2.0–3.0)                           | 2.0(2.0–3.0)                              |
| Borg scale score, median (IQR), units              | 4.0(3.0–5.0)                           | 4.0(3.0–5.0)                              |
| pH, median (IQR), units                             | 7.40(7.37–7.42)                        | 7.40(7.37–7.43)                           |
| PaCO₂ median (IQR), mmHg                           | 50.4(47.3–56.3)                        | 51.7(47.6–58.0)                           |
| PaO₂ median (IQR), mmHg                            | 70.4(57.0–83.0)                        | 68.0(56.0–83.7)                           |
| Bicarbonate, median (IQR), mmol/L                  | 31.3(28.3–34.9)                        | 31.8(29.0–35.2)                           |
| White blood cell, median (IQR), × 10⁹/L            | 6.9(5.5–9.4)                           | 6.9(5.8–8.8)                              |
| C-reactive protein, median (IQR), mg/L              | 10.0(3.9–29.1)                         | 8.7(4.1–30.9)                             |

APACHE II acute physiology and chronic health evaluation II, FEV1 forced expiratory volume in one second, FVC forced vital capacity, IQR interquartile range, PaCO₂ arterial partial pressure of carbon dioxide, PaO₂ arterial partial pressure of oxygen, SpO₂ oxygen saturation

*Calculated as weight in kilograms divided by height in meters squared

Primary outcome
Compared to the COT group, the HFNC group had a similar proportion of patients who met the criteria for intubation (2.5% [n = 4] in the HFNC group vs. 0.6% [n = 1] in the COT group, P = 0.198 without center
random effect, and \( P = 0.186 \) after adjustment for center random effect) (Table 2).

### Secondary outcomes

There was no significant difference in the rate of treatment failure between the groups (15.8% [\( n = 25 \)] vs. 14.5% [\( n = 25 \)] in the HFNC and COT groups, respectively; \( P = 0.745 \) (Table 2). The most common reason for treatment failure in the HFNC group was intolerance to HFNC treatment (\( n = 13, 52.0\% \)), and the most common reason for treatment failure in the COT group was need for NPPV (\( n = 18, 72\% \)) (Table 2).

Patients upgraded to NPPV in both groups were comparable (15 [9.5%] in the HFNC group vs. 22 [12.8%] in the COT group; \( P = 0.343 \) (Table 2). However, compared to the COT group, the median duration from randomization to the start of NPPV treatment was longer in the HFNC group (4.0 [IQR, 3.0–8.0] vs. 2.0 [IQR, 1.0–5.0] days; \( P = 0.060 \). The median total duration of NPPV treatment was similar between the groups (HFNC 6.0 days vs. COT 5.5 days; \( P = 0.780 \) (Table 2).

In this study, a total of five patients reached the predetermined criteria for intubation, of whom four were directly intubated and treated with invasive ventilation (HFNC group, \( n = 3 \); COT group, \( n = 1 \)), and one patient in the HFNC group was successfully treated with NPPV. There was no significant difference in the actual intubation rate between the two groups (\( P = 0.353 \) (Table 2).

There were no deaths in the HFNC group during hospitalization, and one patient in the COT group died of ventilator-associated pneumonia and septic shock after intubation (Table 2). Compared with the COT group, patients in the HFNC group had a significantly longer median length of hospital stay (9.0 [IQR, 7.0–13.0] vs. 8.0 [IQR, 7.0–11.0] days, \( P = 0.021 \). HFNC increased the median hospital cost by about 14.6% compared to the COT group (approximately $2298 [IQR, $1613–$3782] vs. $2005 [IQR, $1439–$2968]; \( P = 0.006 \) (Table 2).

During the 90-day follow-up period after randomization, the mortality rate was not significantly different between the two groups (3.3% vs. 2.9% in the HFNC and COT groups, respectively; \( P > 0.999 \) (Table 2 and Fig. 3). The proportions of readmission due to exacerbation in both groups were 16.3% and 13.5% in the HFNC and COT groups, respectively, with no statistical difference (\( P = 0.478 \) (Table 2 and Fig. 2). Considering deaths as competing events, time to readmission for acute exacerbation was also similar in two groups (Gray’s test \( P = 0.3979 \), Additional file 4: Figure S1).

### Exploratory outcomes

Within 72 h of randomization, there were no significant differences in \( \text{PaCO}_2 \), \( \text{PaO}_2 \), \( \text{SpO}_2 \), respiratory rate, Borg dyspnoea scale score, and airway dryness score (mouth, nose, and throat) between the groups (Fig. 3 and Additional file 1: Table S1). During the study, no severe adverse events attributable to the randomization group were observed.

### Table 1: Primary and secondary outcomes

| Characteristic                      | No. (%) | Absolute difference, % (95%CI) |
|-------------------------------------|---------|-------------------------------|
|                                     | High-flow nasal cannula group (\( n = 158 \)) | Conventional oxygen therapy group (\( n = 172 \)) |
|                                     | \( n \) (%) | \( n \) (%) | \( P \) |
| Primary outcome                     |         |                               | |
| Criteria for intubation, \( n \) (%)| 4 (2.5%) | 1 (0.6%) | 1.95 (−0.8–4.7) | 0.198* |
| Secondary outcome                   |         |                               | |
| Treatment failure, \( n \) (%)     | 25 (15.8%) | 25 (14.5%) | 1.29 (−6.5–9.0) | 0.745* |
| Intubation, \( n \) (%)            | 3 (1.9%) | 1 (0.6%) | 1.95 (−0.8–4.7) | 0.353* |
| NPPV, \( n \) (%)                  | 15 (9.5%) | 22 (12.8%) | −3.3 (−10.1–3.5) | 0.343* |
| Duration of NPPV, median (IQR), days| 6.0 (2.0–10.0) | 5.5 (4.0–8.0) | −1.0 (−2.7–4.7) | 0.780† |
| Mortality in hospital, \( n \) (%)  | 0 (0%) | 1 (0.6%) | >0.999* |
| Mortality at day 90, \( n \) (%)    | 5/153 (3.3%) | 5/171 (2.9%) | 0.34 (−3.4–4.1) | >0.999* |
| Length of hospital stay, median (IQR), days | 9.0 (7.0–13.0) | 8.0 (7.0–11.0) | 1.0 (0.0–2.0) | 0.021† |
| Hospital cost, median (IQR), $      | 2298 (1613–3782) | 2005 (1439–2968) | 265 (−104–632) | 0.006† |
| Readmission rate at day 90, \( n \) (%) | 25/153 (16.3%) | 23/170 (13.5%) | 2.8 (−5.0–10.6) | 0.478* |

* Fishe exact test or \( \chi^2 \)
† Mann–Whitney U
Discussion

In this multicenter randomized clinical trial, we found that compared with COT, HFNC did not reduce need for intubation during hospitalization in non-acidotic patients with acute COPD exacerbation with mild hypercapnia; furthermore, it increased the length of hospital stay and hospital costs.

In this study, we found there was an insignificant difference in the proportion of patients who met the predetermined criteria for intubation between the HFNC and COT groups; however, it was significantly lower than previously expected value [6] in the COT group. This may be related to the significant improvement of clinical management of patients with acute COPD exacerbation in recent years, including the extensive use of NPPV during acute exacerbation, which have remarkably reduced the need for intubation [1–3]. Because of the low rate of intubation, consequently a difference on the primary outcome of need for intubation between the two groups was difficult to demonstrate.
However, it is noteworthy that the length of hospital stay and hospital cost in the HFNC group were significantly higher than those in the COT group. The length of hospital stay of the COT group in our study was similar to that reported in recent studies [29, 30] with comparable underlying lung function. We found that the median duration from randomization to the start of NPPV treatment was longer in the HFNC group than in the COT group (4.0 vs. 2.0 days), which may delay the upgrade of NPPV treatment and increase the length of hospital stay. In addition, the lack of experience with this new technology among COPD patients on general respiratory wards may impact the length of hospital stay and hospital costs. Furthermore, it is worth noting that higher HFNC gas flow would lead to a large amount of oxygen consumption and an increase in medical cost. This factor should be considered especially in clinical scenarios with serious oxygen shortages because oxygen is not an inexhaustible resource. Therefore, these outcomes need to be investigated further in the future clinical studies.

Previous studies showed that HFNC was well tolerated in patients with acute hypoxic respiratory failure; however, its adherence in hypercapnia respiratory failure is rarely explored [20]. Similar to the report of Fraser, et al. [18], we also found that the tolerance of HFNC was not superior to COT, and intolerance (52%) was the main reason for the treatment failure in HFNC group. It may be related to the milder illness severity in our patients, which is similar to the intolerance of NPPV reported in patients with COPD exacerbation with mild hypercapnia [5, 7]. Therefore, the HFNC flow rate (median 30 L/min) adjusted according to patient’s maximum tolerance in our study was obviously lower than that used in patients with acute hypoxic respiratory failure (50–60 L/min) [14–16]. However, the HFNC flow rate was comparable to that in previous clinical physiological studies [20–22, 31–33] showing the physiological advantage of HFNC treatment in COPD patients.

Recently, Cortegiani et al. [34] found that HFNC and NPPV can equally reduce PaCO₂ levels in patients with mild-to-moderate COPD exacerbation (pH 7.25–7.35; PaCO₂ ≥ 55 mmHg) after 2 h of treatment. In our study, HFNC was not associated with lower PaCO₂ levels and dyspnoea compared with COT. In addition to the lower HFNC flow rate than that of Cortegiani et al.’s study, another possible reason is that the baseline severity of hypercapnia (PaCO₂) and the degree of dyspnoea (Borg score and respiratory rate) of the patients included in this study were significantly lower than those of patients in the above physiological study [17–20]. Recent studies have shown that individual responses to HFNC are heterogeneous in patients with acute COPD exacerbations [31], which may be related to the baseline PaCO₂ level [35]. Therefore, whether the clinical outcomes of acute COPD exacerbation patients with acute respiratory acidosis (pH < 7.35) could benefit most from HFNC treatment needs to be explored further.

Another potential advantage of HFNC is that it may reduce the patient’s need for NPPV. The need for NPPV in our patients is similar to that in another study with a comparable underlying lung function (forced expiratory volume in one second % predicted about 32%) [29]. In this study, the NPPV rate was lower in the HFNC group than in the COT group; however, the difference was not statistically significant. In contrast, in a recently published randomized clinical trial, Li et al. [36] found that HFNC can significantly reduce the demand for NPPV compared to nasal prong in milder acute COPD exacerbation patients (forced expiratory volume in one second % predicted about 60%), and compared to our study, more patients needed to be supported with NPPV in Li et al.’s study (19.4% vs. 10.4%). The reasons for the differences between the two studies are difficult to explain clearly. However, compared with our study, patients in the Li et al. [36] were more severely ill during acute exacerbations with a higher APACHE II score (14.7 vs. 10.0) and lower oxygenation (PaO₂ 55 vs. 70 mmHg). A recently published study has shown that HFNC is more effective than COT in patients with moderate acute hypoxic respiratory failure [14]. This may be one of the main reasons why the two studies have different results.

To our knowledge, this study is the largest muticenter clinical trial to explore the use of HFNC in patients with acute COPD exacerbation with mild hypercapnia. However, the present study has several limitations. First, the proportion of patients who met the criteria for intubation in our study was much lower than that the expected value [6], so the study power was limited. According to the results of our data, if the study reaches 80% efficacy and 0.05 significant, a larger sample size of 1474 is required to achieve a significant difference between the two treatment groups. Second, due to the nature of the technical characteristics of the intervention group, it was difficult to achieve a double-blind design. To mitigate this unavoidable bias, investigators were not involved in the clinical decision-making process; besides, the database was controlled by a third party unaware of the study design and outcomes. Third, due to the difficulty of calculating the true cost of hospital admissions, the cost in the study was just a rough value. Finally, of 1276 patients with acute exacerbation of COPD with mild hypercapnia screened, 445 patients (35%) refused to participate in this study, and it might increase the selection bias. However, there was no significant difference in age, gender, SpO₂, and arterial blood gas on admission between those who
declined to participate and the enrolled patients (Additional file 3: Table S3).

Conclusions
In this multicenter randomized controlled study, HFNC compared to COT did not reduce the need for intubation among patients with acute COPD exacerbation with mild hypercapnia; secondary analyses suggested HFNC increased the length of hospital stay and hospital costs. The future studies should focus on patients with acute COPD exacerbation with respiratory acidosis (pH < 7.35). However, because the primary outcome rate was well below expected, the study was underpowered to show a meaningful difference between the two treatment groups.

Abbreviations
APACHE: Acute physiology and chronic health evaluation; COPD: Chronic obstructive pulmonary disease; COT: Conventional oxygen therapy; FIO2: Fraction of inspiration oxygen; HFNC: High-flow nasal cannula; IQR: Interquartile ranges; NPPV: Non-invasive positive pressure ventilation; PaCO2: Arterial partial pressure of carbon dioxide; PaO2: Arterial partial pressure of oxygen; SpO2: Oxygen saturation.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13054-022-03973-7.

Additional file 1. Table S1: Settings of treatment, vital sign, Borg scores, airway dryness score and blood gas analysis between the conventional oxygen therapy group and the high-flow nasal cannula group within 72 hours after randomization.

Additional file 2. Table S2: Comparison of daily duration of treatment with 7 days after randomization, the time of treatment failure and noninvasive positive pressure ventilation start between the conventional oxygen therapy group and the high-flow nasal cannula group.

Additional file 3. Table S3: The comparison of age, gender, oxygenation and blood gas parameters on admission between the enrolled patients and the declined patients.

Additional file 4. Figure S1: Kaplan-Meier analysis of time since readmission during 90 days follow-up period. The cumulative incidence function and Gray’s test were used to consider deaths as competing events to evaluate the difference of time to readmission for acute exacerbation between two groups.

Acknowledgements
The authors would like to thank all medical staff involved in the treatment of enrolled patients at each participating center, and Prof. Xiaoxia Peng, Dr. Guohui Fan, and Dr. Yaowen Zhang for providing writing assistance in the development of this manuscript.

Author contributions
All authors took part in substantial contributions to study conception and design. JX, SG, CY, HL, PP, WL, JZ, MJ, ZC, YC, HB, HL, XL, XH, and QZ involved in interpretation of data; CL, HZ, RL, LZ, CH, CW, FL, MC, CYan, HT, YY, YG, PH, WG, YZ, YF, and CT involved in acquisition of data; CL, JX, SG took part in analysis of data; all authors involved in drafting the article or revising the article critically for important intellectual content; all authors involved in approval of final manuscript. QZ has full access to all data from the study and takes responsibility for the integrity of the data, the accuracy of the data analysis, and for the decision to submit for publication. All authors read and approved the final manuscript.

Funding
This study was funded by National Key Research and Development Program of China (Nos. 2016YFC1304304, 2020YFC2003705); National Natural Science Foundation of China (No. 81870707); Non-profit Central Research Institute Fund of CAMS (No. 2019TX320006).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
It is approved by the ethics committee of China-Japan Friendship Hospital (No. 2017-11) and the local ethics committee of all the study centers.

Consent for publication
Not applicable.

Competing interests
Dr. Qingyuan Zhan received high-flow nasal cannula equipments from Fisher & Paykel Healthcare, Auckland, New Zealand, for the study. The remaining authors declare no conflicts of interest.

Author details
1Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, No. 2 East Yinghua Road, Chaoyang District, Beijing 100029, China. 2National Center for Respiratory Medicine, Beijing, China. 3Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China. 4National Clinical Research Center for Respiratory Diseases, Beijing, China. 5School of Biological Science and Medical Engineering, Beihang University, Beijing, China. 6Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China. 7Department of Pulmonary and Critical Care Medicine, The People’s Hospital of Yuxi City, The Sixth Affiliated Hospital of Kunming Medical University, Yuxi, China. 8Department of Pulmonary and Critical Care Medicine, Inner Mongolia People’s Hospital, No. 20 Zhaowu Road, Hohhot 010017, China. 9Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, No.139 Renmin Middle Road, Changsha 410011, China. 10Department of Pulmonary and Critical Care Medicine, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha 410008, China. 11Department of Pulmonary and Critical Care Medicine, Xiangtan Central Hospital, Xiangtan, China. 12Department of Pulmonary and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. 13Wuhan Research Center for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences, Wuhan, China. 14Department of Pulmonary and Critical Care Medicine, Fujian Provincial Hospital, Fuzhou, China. 15Department of Pulmonary and Critical Care Medicine, Calmette Hospital and The First Hospital of Kunming, Kunming, China. 16Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. 17Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China. 18Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China. 19Chinese Alliance for Respiratory Diseases in Primary Care, Beijing, China. 20Department of Pulmonary and Critical Care Medicine, North China University of Science and Technology Affiliated Hospital, Tangshan, China. 21Department of Pulmonary and Critical Care Medicine, The Third People’s Hospital of Datong, Datong, China. 22Department of Critical Care Medicine, Ruian Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China. 23Department of Respiratory Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Received: 25 January 2022 Accepted: 30 March 2022
Published online: 15 April 2022
References

1. Odaikun CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017(7):CD004104.

2. Lindenauer PK, Stefan MS, Sheih MS, Pekow PS, Rothberg MB, Hill NS. Hospital patterns of mechanical ventilation for patients with exacerbations of COPD. Ann Am Thorac Soc. 2015;12:402–9.

3. Chandra D, Stamm JA, Taylor B, Ramos RM, Satterwhite L, Krishnan JA, et al. Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998–2008. Am J Respir Crit Care Med. 2012;185:152–9.

4. Rochweg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017.50(2):160246.

5. Keenan SP, Powers CE, McCormack DG. Noninvasive positive-pressure ventilation in patients with milder chronic obstructive pulmonary disease exacerbations: a randomized controlled trial. Respir Care. 2005;50:610–6.

6. Collaborative Research Group of Noninvasive Mechanical Ventilation for Chronic Obstructive Pulmonary Disease. Early use of non-invasive positive pressure ventilation for acute exacerbations of chronic obstructive pulmonary disease: a multicentre randomized controlled trial. Chin Med J (Engl). 2005;118:2034–2040.

7. Bardi G, Pierotto R, Desideri M, Valdisseri L, Bottai M, Palla A. Nasal ventilation in COPD exacerbations: early and late results of a prospective, controlled study. Eur Respir J. 2000;15:98–104.

8. Spolletini G, Alothabi M, Blasi F, Hill NS. Heated Humidified High-Flow Nasal Oxygen in Adults: Mechanisms of Action and Clinical Implications. Chest. 2015;148:253–61.

9. Ischaki E, Pantazopoulos I, Zakynthinos S. Nasal high flow therapy: a novel treatment rather than a more expensive device. Eur Respir Rev. 2017;26(145):170028.

10. Maggiore SM, Idone FA, Vaschetto R, Cataldo A, Antonicelli F, et al. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med. 2014;190:262–268.

11. Rochweg B, Granton T, Wang DX, Helvzy Y, Einav S, Frat JP, et al. High-flow nasal cannula compared with conventional oxygen therapy for acute hypoxic respiratory failure: a systematic review and meta-analysis. Intensive Care Med. 2019;45:563–72.

12. Ni YN, Luo J, Yu H, Liu D, Ni Z, Cheng J, et al. Can High-flow Nasal Cannula Reduce the Rate of Endotracheal Intubation in Adult Patients With Acute Respiratory Failure Compared With Conventional Oxygen Therapy and Noninvasive Positive Pressure Ventilation?. A Systematic Review and Meta-analysis. Chest. 2017;151:764–75.

13. Lu Z, Chang W, Meng SS, Zhang X, Xie J, Xu JY, et al. Effect of high-flow nasal cannula oxygen therapy compared with conventional oxygen therapy in postoperative patients: a systematic review and meta-analysis. BMJ Open. 2019;9:e027523.

14. Frat JP, Thille AW, Mercart A, Girault C, Ragot S, Perret S, et al. High-flow oxygen through nasal cannula in acute hypoxic respiratory failure. N Engl J Med. 2015;372:2185–96.

15. Herrández G, Vaquero C, González P, Subira C, Frutos-Vivar F, Rialp G, et al. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reinstitution in Low-Risk Patients: A Randomized Clinical Trial. JAMA. 2016;315:1354–61.

16. Stéphan F, Barrand C, Petit P, Rézaïguia-Declaux S, Médard A, Delannoy B, et al. High-Flow Nasal Oxygen Versus Noninvasive Positive Airway Pressure in Hypoxic Patients After Cardiothoracic Surgery: A Randomized Clinical Trial. JAMA. 2015;313:2331–9.

17. Braunlich J, Köhler M, Wirtz H. Nasal highflow improves ventilation in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1077–85.

18. Fraser JF, Spooner AJ, Dunster KR, Anstey CM, Corley A. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomized crossover trial. Thorax. 2016;71:59–61.

19. Jeong JH, Kim DH, Kim SC, Kang C, Lee SH, Kang TS, et al. Changes in arterial blood gases after use of high-flow nasal cannula therapy in the ED. Am J Emerg Med. 2015;33:1344–9.

20. Pilcher J, Eastlake L, Richards M, Power S, Cripps T, Bibby S, et al. Physiological effects of titrated oxygen via nasal high-flow cannulae in COPD exacerbations: A randomized controlled cross-over trial. Respiriogy. 2017;22:1149–55.

21. Biselli PJ, Fricke K, Grote L, Braun AT, Kirkness J, Smith P, et al. Reductions in dead space ventilation with nasal high flow depend on physiological dead space volume: metabolic hood measurements during sleep in patients with COPD and controls. Eur Respir J. 2018;51(3):170251.

22. Biselli PJ, Kirkness J, Grote L, Fricke K, Schwartz AR, Smith P, et al. Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study. J Appl Physiol. 1985;17(122):82–8.

23. Longhini F, Pisani L, Lunghi R, Cornelli V, Brun A, Garofalo E, et al. High-Flow Oxygen Therapy After Noninvasive Ventilation Interruption in Patients Recovering From Hypercapnic Acute Respiratory Failure: A Physiological Crossover Trial. Crit Care Med. 2019;47:e506–11.

24. Di Mussi R, Spadaro S, Stripoli T, Volta CA, Trenzoli P, Ferrari P, et al. High-flow nasal cannula oxygen therapy decreases postextubation neuroventilatory drive and work of breathing in patients with chronic obstructive pulmonary disease. Crit Care. 2018;22:180.

25. Rea H, McAuley S, Jayaram L, Garrett J, Hockey H, Storey L, et al. The clinical utility of long-term humidification therapy in chronic airway disease. Respir Med. 2010;104:525–33.

26. Storgaard LH, Hockey HU, Laursen BS, Weinrich UM. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis. 2018;13:1195–205.

27. Nagata K, Kikuchi T, Horie T, Shinak A, Kitajima T, Kadowaki T, et al. Domestic High-Flow Nasal Cannula Oxygen Therapy for Patients with Stable Hypercapnic Chronic Obstructive Pulmonary Disease. A Multicenter Randomized Crossover Trial. Ann Am Thorac Soc. 2018;15:432–439.

28. Patrick W, Webster K, Ludwig L, Roberts D, Weibe P, Younes M. Noninvasive positive-pressure ventilation in acute respiratory distress without prior chronic respiratory failure. Am J Respir Crit Care Med. 1996;153:1005–11.

29. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Brihl M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309:2223–31.

30. Sivapalan P, Lapperre TS, Janner J, Laub RR, Moberg M, Bech CS, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019;7(8):699–709.

31. Nilus G, Franke KJ, Domanski U, Rühle KH, Kirkness J, Schneider H. Effects of nasal insufflation on arterial gas exchange and breathing pattern in patients with chronic obstructive pulmonary disease and hypercapnic respiratory failure. Adv Exp Med Biol. 2013;755:27–34.

32. Braunlich J, Mauersberger F, Wirtz H. Effectiveness of nasopharyngeal hypercapnic COPD patients is flow and leakage dependent. BMJ Pulm Med. 2018;14:181.

33. Rittayamai N, Phuangchone P, Thocharuk J, Phruekhiart N, Brochard L. Effects of high-flow nasal cannula and non-invasive ventilation on inspiratory effort in hypercapnic patients with chronic obstructive pulmonary disease: a preliminary study. Ann Intensive Care. 2019;9:122.

34. Cortegiani A, Longhini F, Madotto F, Groff P, Scala R, Cimini C, et al. High flow nasal therapy versus noninvasive ventilation as initial ventilatory strategy in COPD exacerbation: a multicenter non-inferiority randomized trial. Crit Care. 2020;24:692.

35. Braunlich J, Mauersberger F, Wirtz H. Effectiveness of nasal highflow in hypercapnic COPD patients is flow and leakage dependent. BMC Pulm Med. 2018;14:181.

36. Rittayamai N, Phuangchone P, Thocharuk J, Phruekhiart N, Brochard L. Effects of high-flow nasal cannula and non-invasive ventilation on inspiratory effort in hypercapnic patients with chronic obstructive pulmonary disease: a preliminary study. Ann Intensive Care. 2019;9:122.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.